Jason Wittes
Stock Analyst at Roth Capital
(2.60)
# 1,812
Out of 5,182 analysts
58
Total ratings
48.08%
Success rate
3.75%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $7.95 | +403.14% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $329.01 | +38.60% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.27 | +604.85% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $12.32 | +78.57% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $89.01 | -19.11% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.50 | +144.44% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $93.70 | +22.73% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $5.26 | +109.13% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $114.52 | -12.68% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.93 | +159.07% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.44 | +1,924.29% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $24.54 | +205.62% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $10.36 | +112.36% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $92.59 | +29.60% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.66 | +15.30% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $198.70 | -27.03% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $16.50 | -54.55% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $12.48 | +1,502.56% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $35.38 | -26.51% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $7.95
Upside: +403.14%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $329.01
Upside: +38.60%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.27
Upside: +604.85%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $12.32
Upside: +78.57%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $89.01
Upside: -19.11%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.50
Upside: +144.44%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $93.70
Upside: +22.73%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $5.26
Upside: +109.13%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $114.52
Upside: -12.68%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.44
Upside: +1,924.29%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $24.54
Upside: +205.62%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $10.36
Upside: +112.36%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $92.59
Upside: +29.60%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.66
Upside: +15.30%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $198.70
Upside: -27.03%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $16.50
Upside: -54.55%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $12.48
Upside: +1,502.56%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $35.38
Upside: -26.51%